• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Breast MRI can be cost-effective for some women


A computer model simulation suggests that adding breast MRI screening may be cost-effective for women of certain ages who carry BRCA1 and BRCA2 gene mutations, according to Stanford University researchers.

A computer model simulation suggests that adding breast MRI screening may be cost-effective for women of certain ages who carry BRCA1 and BRCA2 gene mutations, according to Stanford University researchers.

Women who inherit mutations in the BRCA1 or BRCA2 cancer susceptibility genes have a 45% to 65% lifetime risk of developing breast cancer. The risk can be reduced by prophylactic mastectomy, but many BRCA1/2 mutation carriers choose instead to seek effective screening strategies that detect breast cancer early.

Screening with contrast-enhanced breast MRI has been shown to detect disease earlier than mammography in high-risk women. Cancers detected by MRI are often axillary lymph-node negative and stage I.

Although breast MRI screening is highly sensitive, it increases the rate of false-positive test results and has not been shown to reduce the death rate from breast cancer.

Breast MRI screening is at least 10 times more expensive than mammographic screening and generates higher diagnostic costs. Because cost may be the greatest barrier to broader evaluation and dissemination of breast MRI screening, cost-effectiveness is a critical consideration.

Sylvia K. Plevritis, Ph.D., and colleagues evaluated the cost-effectiveness of adding breast MRI screening in BRCA1/2 mutation carriers. A computer model was used that simulates the life histories of individual BRCA1/2 mutation carriers, incorporating the effects of mammographic and MRI screening (JAMA 2006;295:2374-2384).

The accuracy of mammography and breast MRI was estimated from published data in high-risk women. Breast cancer survival in the absence of screening was based on the Surveillance, Epidemiology, and End Results database of breast cancer patients diagnosed in the prescreening period (1975 to 1981), adjusted for the current use of supplemental therapy. Utilization rates and costs of diagnostic and treatment interventions were based on a combination of published literature and Medicare payments for 2005.

At a cost-effectiveness threshold of $100,000 per quality-adjusted life-year gained, adding annual MRI from ages 35 to 54 years is cost-effective among all BRCA1 mutation carriers and among BRCA2 mutation carriers for whom mammography is insensitive, according to the study.

MRI has a larger role in screening BRCA1 mutation carriers because they are at greater risk for developing breast cancer and their cancers are more aggressive than those that develop in BRCA2 mutation carriers, the authors write.

They add that screening with MRI becomes more cost-effective as breast cancer risk increases, mammography performance worsens, greater quality of life gains accrue from MRI, and the cost of MRI decreases.

"With substantial declines in its cost, breast MRI screening is likely to represent an acceptable value for a broader group of women," Plevritis said.

For more information from the Diagnostic Imaging archives:

Dynamic CE-MRI excels as screening test for women carrying genetic risks for breast cancer

Dedicated breast MR system cracks mainstream practice

Dynamic contrast-enhanced MR imaging finally comes of age

Three-T matures to meet expanding clinical needs

Recent Videos
Where the USPSTF Breast Cancer Screening Recommendations Fall Short: An Interview with Stacy Smith-Foley, MD
A Closer Look at MRI-Guided Transurethral Ultrasound Ablation for Intermediate Risk Prostate Cancer
Improving the Quality of Breast MRI Acquisition and Processing
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Nina Kottler, MD, MS
Practical Insights on CT and MRI Neuroimaging and Reporting for Stroke Patients
Related Content
© 2024 MJH Life Sciences

All rights reserved.